News

Outcomes among more than 1,800 people newly diagnosed with cardiac sarcoidosis differed by diagnostic features, including heart tissue sampling to confirm the disease and whether it also affected other organs, a large real-world study using registry data found. The group of patients diagnosed without a heart biopsy and with…

A study examining patients’ blood and lymph nodes at the time of sarcoidosis diagnosis and before treatment found signs of inflammation but no detectable microorganisms, challenging the long-held hypothesis that infectious microorganisms may cause sarcoidosis. “Our findings demonstrate that the inflammatory response…

Over the coming months, Atyr Pharma will be working toward the launch of a global clinical trial testing its therapy candidate efzofitimod in people with moderate to severe pulmonary sarcoidosis and restrictive lung disease, which together make it difficult for the lungs to fully expand, hampering breathing. The…

People with sarcoidosis but no documented liver involvement have a nearly threefold higher risk of developing permanent liver scarring (cirrhosis) than those without the inflammatory disease, according to a large, population-based study from Israel. The risk was particularly elevated among patients whose sarcoidosis affected multiple organs. Still, the absolute…

Heart inflammation that persists after initial treatment may signal disease relapse in people with cardiac sarcoidosis, and advanced imaging could help identify patients who warrant monitoring, a study found. Most relapses occurred in areas of the heart that had previously been affected, and more than half of patients with…

Three genes not previously established as major genetic contributors to sarcoidosis — RFTN2, FAM117B, and RNF215 — may influence a person’s susceptibility to the inflammatory disease, according to a large genetic analysis. Using genetic information from more than 5,000 people living with sarcoidosis and nearly 500,000 without the disease,…

Sarcoidosis patients, caregivers, healthcare professionals, and researchers in the Mid-Atlantic will have the opportunity to come together to strengthen sarcoidosis care and build support networks at a free summit on Sept. 26 in Philadelphia. The Foundation for Sarcoidosis Research (FSR) is hosting the regional summit to allow patients…

Several types of immune cells and immune signaling molecules are altered in people with cardiac sarcoidosis, a new study shows. These findings “may further elucidate the complex, and yet not well understood, [disease-driving] pathways in cardiac sarcoidosis,” the researchers wrote. Although more studies are needed to validate the findings,…

Sarcoidosis appears to follow two main trajectories, and clinical and treatment features at diagnosis may help predict whether the disease will resolve within the first few years or persist, according to a large study in Sweden involving more than 9,000 adult patients. About seven in 10 patients had few…

The first participants have been enrolled in a global clinical trial that will test Priovant Therapeutics’ oral therapy candidate brepocitinib against a placebo in people with cutaneous sarcoidosis (CS) — a type of the autoimmune disease, with no approved treatments, in which clumps of immune cells form in…